Investors

2023

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces the Annual General Meeting will be held on 11 June 2019 at 3pm at Foxhills Country Club, Stonehill Road, Ottershaw, Surrey KT16 0EL.

A copy of the notice of AGM will be available on the Company's website today.

Notice of Annual General Meeting to be held on 11 June 2019

Proxy for use at the Annual General Meeting to be held on 11 June 2019

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company´s current areas of focus include obesity, cardiovascular health, and diabetes.

2022

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces the Annual General Meeting will be held on 11 June 2019 at 3pm at Foxhills Country Club, Stonehill Road, Ottershaw, Surrey KT16 0EL.

A copy of the notice of AGM will be available on the Company's website today.

Notice of Annual General Meeting to be held on 11 June 2019

Proxy for use at the Annual General Meeting to be held on 11 June 2019

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company´s current areas of focus include obesity, cardiovascular health, and diabetes.

2021

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces the Annual General Meeting will be held on 11 June 2019 at 3pm at Foxhills Country Club, Stonehill Road, Ottershaw, Surrey KT16 0EL.

A copy of the notice of AGM will be available on the Company's website today.

Notice of Annual General Meeting to be held on 11 June 2019

Proxy for use at the Annual General Meeting to be held on 11 June 2019

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company´s current areas of focus include obesity, cardiovascular health, and diabetes.

2020

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces the Annual General Meeting will be held on 11 June 2019 at 3pm at Foxhills Country Club, Stonehill Road, Ottershaw, Surrey KT16 0EL.

A copy of the notice of AGM will be available on the Company's website today.

Notice of Annual General Meeting to be held on 11 June 2019

Proxy for use at the Annual General Meeting to be held on 11 June 2019

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company´s current areas of focus include obesity, cardiovascular health, and diabetes.

2019

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces the Annual General Meeting will be held on 11 June 2019 at 3pm at Foxhills Country Club, Stonehill Road, Ottershaw, Surrey KT16 0EL.

A copy of the notice of AGM will be available on the Company's website today.

Notice of Annual General Meeting to be held on 11 June 2019

Proxy for use at the Annual General Meeting to be held on 11 June 2019

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company´s current areas of focus include obesity, cardiovascular health, and diabetes.

2018

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces the Annual General Meeting will be held on 11 June 2019 at 3pm at Foxhills Country Club, Stonehill Road, Ottershaw, Surrey KT16 0EL.

A copy of the notice of AGM will be available on the Company's website today.

Notice of Annual General Meeting to be held on 11 June 2019

Proxy for use at the Annual General Meeting to be held on 11 June 2019

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company´s current areas of focus include obesity, cardiovascular health, and diabetes.